{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:38:52Z","timestamp":1792809532723,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"F. Hoffmann-La Roche Ltd.","id":[{"id":"https:\/\/ror.org\/00by1q217","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40123-026-01489-9","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:16:19Z","timestamp":1789647379000},"page":"3927-3937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON\/COMINO Post Hoc Analysis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-4771","authenticated-orcid":false,"given":"Christiana","family":"Dinah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harit K.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0606-9004","authenticated-orcid":false,"given":"Hemal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan J.","family":"Suner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Dagincourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9312-9924","authenticated-orcid":false,"given":"Liliana P.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joern","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Danzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"3","key":"1489_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jamaophthalmol.2025.5658","volume":"144","author":"JP Ehlers","year":"2026","unstructured":"Ehlers JP, Josic K, Aiello LP, et al. Ultra-widefield fluorescein angiographic quantitative leakage parameters and clinical outcomes in nonproliferative diabetic retinopathy. JAMA Ophthalmol. 2026;144(3):221\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"1489_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaophthalmol.2021.5619","volume":"140","author":"S Gurudas","year":"2022","unstructured":"Gurudas S, Patrao N, Nicholson L, et al. Visual outcomes associated with patterns of macular edema resolution in central retinal vein occlusion treated with anti\u2013vascular endothelial growth factor therapy: a post hoc analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) trial. JAMA Ophthalmol. 2022;140(2):143\u201350.","journal-title":"JAMA Ophthalmol."},{"key":"1489_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2019.03.029","volume":"205","author":"M Iftikhar","year":"2019","unstructured":"Iftikhar M, Mir TA, Hafiz G, et al. Loss of peak vision in retinal vein occlusion patients treated for macular edema. Am J Ophthalmol. 2019;205:17\u201326.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1489_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ, et al. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2025;263(5):1239\u201347.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1489_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1646806","volume":"16","author":"Y Jing","year":"2025","unstructured":"Jing Y, Li D. Faricimab for retinal vein occlusion: a review of current evidence and future perspectives. Front Pharmacol. 2025;16:1646806.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1489_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35(5):1305\u201316.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1489_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcp.10442","volume":"199","author":"Y Oshima","year":"2004","unstructured":"Oshima Y, Deering T, Oshima S, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004;199(3):412\u20137.","journal-title":"J Cell Physiol"},{"issue":"10326","key":"1489_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"issue":"10326","key":"1489_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"9","key":"1489_CR10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","volume":"9","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, et al. Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials. Ophthalmol Retina. 2025;9(9):848\u201359.","journal-title":"Ophthalmol Retina."},{"issue":"8","key":"1489_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, et al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. 2024;131(8):950\u201360.","journal-title":"Ophthalmology."},{"key":"1489_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"L Hattenbach","year":"2023","unstructured":"Hattenbach L, Abreu F, Arrisi P, et al. BALATON and COMINO: phase 3 randomized clinical trials of faricimab for retinal vein occlusion: study design and rationale. Ophthalmol Sci. 2023;3:100302.","journal-title":"Ophthalmol Sci."},{"issue":"6","key":"1489_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.oret.2024.11.015","volume":"9","author":"RA Goldberg","year":"2025","unstructured":"Goldberg RA, Mar FA, Csaky K, et al. Resolution of angiographic macular leakage with faricimab versus aflibercept in patients with diabetic macular edema in YOSEMITE\/RHINE. Ophthalmol Retina. 2025;9(6):515\u201326.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"1489_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.ophtha.2019.05.034","volume":"126","author":"JP Ehlers","year":"2019","unstructured":"Ehlers JP, Jiang AC, Boss JD, et al. Quantitative ultra-widefield angiography and diabetic retinopathy severity: an assessment of panretinal leakage index, ischemic index and microaneurysm count. Ophthalmology. 2019;126(11):1527\u201332.","journal-title":"Ophthalmology."},{"issue":"10","key":"1489_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1097\/IAE.0b013e3181dde5f5","volume":"30","author":"RP Danis","year":"2010","unstructured":"Danis RP, Scott IU, Qin H, et al. Association of fluorescein angiographic features with visual acuity and with optical coherence tomographic and stereoscopic color fundus photographic features of diabetic macular edema in a randomized clinical trial. Retina. 2010;30(10):1627\u201337.","journal-title":"Retina"},{"issue":"11","key":"1489_CR16","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00417-008-0892-6","volume":"246","author":"B Sander","year":"2008","unstructured":"Sander B, Hamann P, Larsen M. A 5-year follow-up of photocoagulation in diabetic macular edema: the prognostic value of vascular leakage for visual loss. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1535\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1489_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2023.103731","volume":"43","author":"G Sun","year":"2023","unstructured":"Sun G, Wang X, Yi Z, He L, Zheng H, Chen C. Distribution of leakage index using ultra-widefield fluorescein angiography in patients with non-ischemic branch retinal vein occlusion and its association with macular edema. Photodiagnosis Photodyn Ther. 2023;43:103731.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"5","key":"1489_CR18","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00417-023-06343-3","volume":"262","author":"G Sun","year":"2024","unstructured":"Sun G, Wang X, Tian M, et al. Relationship between ischemic index, leakage index, and macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2024;262(5):1499\u2013506.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"1489_CR19","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","volume":"105","author":"T Ciulla","year":"2021","unstructured":"Ciulla T, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol. 2021;105(12):1696\u2013704.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1489_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41433-025-04089-2","volume":"40","author":"C Dinah","year":"2026","unstructured":"Dinah C, Dodds M, Lotery A, et al. Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study. Eye (Lond). 2026;40(1):107\u201316.","journal-title":"Eye (Lond)."},{"issue":"7","key":"1489_CR21","first-page":"4886","volume":"65","author":"Y Wang","year":"2024","unstructured":"Wang Y, Hibar D, Maunz A, et al. Impact of early intraretinal fluid reduction on one-year outcomes in diabetic macular edema. Invest Ophthalmol Vis Sci. 2024;65(7):4886.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"8","key":"1489_CR22","first-page":"690","volume":"66","author":"CS Tan","year":"2025","unstructured":"Tan CS, Gallego-Pinazo R, Koh AHC, et al. Baseline and early treatment response variables associated with faricimab durability in treatment-na\u00efve nAMD: TENAYA\/LUCERNE post hoc analyses. Invest Ophthalmol Vis Sci. 2025;66(8):690.","journal-title":"Invest Ophthalmol Vis Sci."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01489-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:03:59Z","timestamp":1792807439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01489-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01489-9","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christiana Dinah has been a consultant for AbbVie, Apellis, Astellas, Boehringer Ingelheim, EyePoint, Janssen, Ocular Therapeutix, Ora Clinical, and Roche; has received lecture fees from Apellis, Astellas, Bayer, Boehringer Ingelheim, Roche, and Topcon; and has received institution grants from Apellis, NIHR, Roche, and Topcon. Harit K. Bhatt has been a consultant for Astellas, Genentech, Inc., and Regeneron; has been a speaker for Astellas; and has equity in Revive and RevOpsis. Hemal Mehta has been a consultant for AbbVie, Apellis, Astellas, Bayer, Boehringer Ingelheim, Ripple, and Roche. Masahiko Shimura has been a consultant for\/received lecture fees from Bayer, Boehringer Ingelheim, Chugai, Kowa, Novartis, Otsuka, Roche, Senju, and Wakamoto and has received travel fees\/honoraria from Chugai. Ivan J. Suner has been an advisory board member for Alimera, Apellis, Genentech, Inc.\/Roche, Iveric Bio\/Astellas, and Regeneron; has been a consultant for Apellis, Genentech, Inc.\/Roche, and Regeneron; has received research support from Alimera, Apellis, Aura, EyePoint, Genentech, Inc.\/Roche, Kodiak, Ocular Therapeutix, and Regeneron; and has been on the speaker\u2019s bureau for Apellis and Genentech, Inc.\/Roche. Xun Xu has nothing to disclose. Nicholas Dagincourt is an employee of Everest Clinical Research and has been a consultant for Genentech, Inc. Liliana Paris Pereira is an employee of Genentech, Inc. Joern Schweitzer is an employee of F. Hoffmann-La Roche Ltd. Carl J. Danzig has been a consultant for 4DMT, AbbVie, Able Tx, Adverum, Apellis, Beacon, Cognition, EyeBio\/Merck, EyePoint, Genentech, Inc., Intellia Therapeutics, Iveric Bio\/Astellas, Lexitas, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Regeneron, Regenxbio, Roche, Samsung Bioepsis, Sanofi, Stealth, and Unity; has received research grants from 4DMT, Adverum, Alexion, Annexon, Apellis, Aviceda, Bayer, Boehringer Ingelheim, Cognition, EyeBio, EyePoint, Genentech, Inc., Iveric Bio\/Astellas, Ocular Therapeutix, Oculis, Regeneron, Roche, Stealth, and Unity; and has been a speaker for Iveric Bio\/Astellas.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials were conducted in accordance with the International Conference on Harmonisation E6 Guideline for Good Clinical Practice and the principles of the Declaration of Helsinki or the laws and regulations of the country in which the research was conducted. Written informed consent was obtained before initiation of study procedures, and the study protocol was approved by institutional review boards before the studies began.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}